Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Voyager Therapeutics (VYGR) Return on Sales (2016 - 2025)

Voyager Therapeutics (VYGR) has disclosed Return on Sales for 11 consecutive years, with 1.78% as the latest value for Q4 2025.

  • Quarterly Return on Sales rose 369.0% to 1.78% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 2.96% through Dec 2025, down 215.0% year-over-year, with the annual reading at 2.97% for FY2025, 215.0% down from the prior year.
  • Return on Sales hit 1.78% in Q4 2025 for Voyager Therapeutics, up from 2.09% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 15.23% in Q4 2022 to a low of 32.4% in Q1 2022.
  • Historically, Return on Sales has averaged 5.79% across 5 years, with a median of 3.01% in 2021.
  • Biggest five-year swings in Return on Sales: crashed -2847bps in 2022 and later surged 3322bps in 2023.
  • Year by year, Return on Sales stood at 0.18% in 2021, then soared by 8353bps to 15.23% in 2022, then tumbled by -96bps to 0.63% in 2023, then tumbled by -975bps to 5.47% in 2024, then skyrocketed by 67bps to 1.78% in 2025.
  • Business Quant data shows Return on Sales for VYGR at 1.78% in Q4 2025, 2.09% in Q3 2025, and 6.42% in Q2 2025.